SPDR S&P Biotech ETF (XBI)
| Assets | $8.37B |
| NAV | $89.54 |
| Expense Ratio | 0.35% |
| PE Ratio | 10.18 |
| Shares Out | 93.45M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Mar 22, 2021 |
| 1-Year Return | -26.75% |
| Volume | 7,732,261 |
| Open | 87.69 |
| Previous Close | 88.87 |
| Day's Range | 86.74 - 88.60 |
| 52-Week Low | 61.78 |
| 52-Week High | 136.61 |
| Beta | 1.08 |
| Holdings | 135 |
| Inception Date | Jan 31, 2006 |
About XBI
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
Top 10 Holdings
16.71% of assets| Name | Symbol | Weight |
|---|---|---|
| Global Blood Therapeutics | GBT | 2.57% |
| Karuna Therapeutics | KRTX | 2.24% |
| ChemoCentryx | CCXI | 1.76% |
| Twist Bioscience | TWST | 1.57% |
| Beam Therapeutics | BEAM | 1.57% |
| Alnylam Pharmaceuticals | ALNY | 1.47% |
| Apellis Pharmaceuticals | APLS | 1.45% |
| PTC Therapeutics | PTCT | 1.38% |
| Sarepta Therapeutics | SRPT | 1.37% |
| Natera | NTRA | 1.34% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 22, 2021 | $0.040 | Mar 25, 2021 |
| Dec 21, 2020 | $0.176 | Dec 24, 2020 |
| Sep 21, 2020 | $0.08897 | Sep 24, 2020 |
| Jun 22, 2020 | $0.01676 | Jun 25, 2020 |
| Dec 20, 2019 | $0.00086 | Dec 26, 2019 |
| Sep 20, 2019 | $0.00319 | Sep 25, 2019 |
News
Biotech ETFs Are on the Mend
Biotechnology sector-related exchange traded funds are making a swift rebound as a spate of dealing making and new drug approvals helped reinvigorate the segment. For instance, the SPDR S&P Biotech ETF ...
Biotech Rebounds on Optimism and Deal Making
The sector had tumbled in the market selloff, but it is getting a boost from big investors and big pharmaceutical companies.
Hedge fund says there are 2 areas in the U.S. in which it has 'aggressive positions'
Thomas Hayes of Great Hill Capital explains why it's positive on U.S. biotech and auto suppliers.
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genom...
Biotech Wins Last Week: 5 Best ETFs
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtu...
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, ...
The Bull Market in Biotech Is Still Going Strong
The SPDR S&P Biotech ETF is up 32.5% since the close of trading on June 14, nearly triple the gain in the S&P 500.
The 3 Best Market Sectors for the Second Half of 2022
Inflation fears delivered the worst first-half performance for the stock market since 1970. Fortunately, the second half is unlikely to echo the destruction because equities have already baked in a mild...
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Smart Beta ETF report for XBI
Is It Time to Buy the Dip With Biotech Stocks?
Right now, it's even riskier to buy biotechs than normal.
Final Trades: XBI, UNH, KWEB & DHR
The final trades of the week. With CNBC's Joe Kernen and the Fast Money traders, Tim Seymour, Jeff Mills, Bonawyn Eison and Steve Grasso.
Final Trades: CVS, Disney, Biotech & more
The "Halftime Report" traders give their top picks to watch for the second half.
Biotech Public Offerings at 10-Year Low
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings...
5 ETFs Riding High on the Biotech Comeback
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Health-care stocks could do well during economic contraction, says Renaissance's Jeff Degraaf
Jeff Degraaf, Renaissance Macro Research chairman, joins 'Closing Bell: Overtime' to discuss biotech and other sectors to watch.
Biotech ETFs Are Making a Comeback
Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Cl...
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Sector ETF report for XBI
Use This 1 Genius Trick for Finding Dirt Cheap Biotech Stocks in the Bear Market
This metric will show you which companies are being valued at potentially unreasonably low levels.
Biotech stocks will ‘outperform' in the balance of 2022: Fahmy
A new bull market is unlikely until the U.S. Federal Reserve starts to go easy on the interest rates. Still, there are opportunities that could be rewarding in the back half of 2022.
Biotech Stocks Finally Rose in June. What Does It Mean?
Not all analysts agree that the sector's gains in June mean its rout is over.
Joseph Fahmy: Biotech is likely to outperform in the second half of the year
Joseph Fahmy, Managing Director at Zor Capital, joins Worldwide Exchange to discuss why he's bullish on biotech stocks, including the XBI ETF.